Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
9.75
+0.35 (3.72%)
At close: Dec 20, 2024, 4:00 PM
9.24
-0.51 (-5.23%)
After-hours: Dec 20, 2024, 7:00 PM EST
Apollomics Employees
Apollomics had 45 employees as of December 31, 2023. The number of employees increased by 2 or 4.65% compared to the previous year.
Employees
45
Change (1Y)
2
Growth (1Y)
4.65%
Revenue / Employee
$46,689
Profits / Employee
-$1,269,178
Market Cap
10.75M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 45 | 2 | 4.65% |
| Dec 31, 2022 | 43 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zhongchao | 142 |
| Lyra Therapeutics | 88 |
| Turnstone Biologics | 80 |
| Jaguar Health | 49 |
| Relmada Therapeutics | 20 |
| BioRestorative Therapies | 11 |
| Immuron | 7 |
| Ensysce Biosciences | 7 |
APLM News
- 1 day ago - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 11 days ago - Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 3 months ago - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewsWire
- 4 months ago - Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial - GlobeNewsWire
- 5 months ago - Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 6 months ago - Apollomics Announces Updated Strategic Focus and Leadership Team Changes - GlobeNewsWire
- 8 months ago - Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene - GlobeNewsWire